Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14092123
Abstract: Simple Summary Second line anti-PD1 immunotherapy is effective in selected BRAF-mutated melanoma patients after BRAFi/MEKi immunotherapy failure. Nivolumab and pembrolizumab are of similar efficacy as a second line therapy. Worse performance status as well as… read more here.
Keywords: pd1 immunotherapy; brafi meki; anti pd1; line ... See more keywords
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms22126288
Abstract: Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-small cell lung cancer (NSCLC) over the past decade. Patient selection is usually based on PD-L1 expression by tumor cells and/or tumor mutational… read more here.
Keywords: anti pd1; lung cancer; cell lung; pd1 immunotherapy ... See more keywords
Eubacterium rectale Improves the Efficacy of Anti-PD1 Immunotherapy in Melanoma via l-Serine-Mediated NK Cell Activation
Sign Up to like & getrecommendations! Published in 2023 at "Research"
DOI: 10.34133/research.0127
Abstract: Natural killer (NK) cells, as key immune cells, play essential roles in tumor cell immune escape and immunotherapy. Accumulating evidence has demonstrated that the gut microbiota community affects the efficacy of anti-PD1 immunotherapy and that… read more here.
Keywords: pd1 immunotherapy; cell; melanoma; immunotherapy ... See more keywords